ClinicalTrials.gg
CompletedNCT00568022Updated Mar 10, 2016Results posted

A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer

A Phase 1 interventional study of Ixabepilone and Capecitabine in Breast Cancer, sponsored by R-Pharm. Completed at 4 sites in Japan. Open to female participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2016-03-10.

Sponsored by R-Pharm · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Non-randomized
Ages
20 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies testing ixabepilone in Breast Neoplasms — none open to participants now, 1 under way, none of them phase 3. ixabepilone · Breast Neoplasms.

Enrollment
36th of 39
9 · median 56
Started
2008
with 10 others
Phase 1
7 of 41
none open now
Registered
15th of 41
by date
Lead sponsor
13 of 41
R-Pharm

Among the 41 studies testing ixabepilone in Breast Neoplasms, this one is the 36th largest by enrollment of the 39 interventional ones that give a count, is one of 11 that started in 2008, is one of 7 in phase 1, and was the 15th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

None of the 41 studies testing ixabepilone in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →

About ixabepilone

ixabepilone: first FDA approval 2007 (IXEMPRA KIT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 20 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 41 studies testing ixabepilone in Breast Neoplasms as a file.
02

Study summary

The purpose of this study is to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and recommended Phase II dose of ixabepilone in combination with capecitabine in Japanese participants with metastatic breast cancer.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women ≥ 20 years
  • or cytologically confirmed diagnosis of adenocarcinoma originating in the breast

Exclusion criteria

Exclusion Criteria:

  • Number of prior chemotherapy in the setting ≥3
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Ixabepilone + Capecitabine

    Drug: Ixabepilone · Drug: Capecitabine

Interventions

  • Ixabepilone: Intravenous (IV) Solution, IV, 32(40)mg/m\^2, once every 3 weeks, up to 6 cycles

    Also known as: IXEMPRA, BMS-247550

  • Capecitabine: Tablets, Oral, 1650(2000)mg/m\^2, twice daily for 2 weeks, one week off, up to 6 cycles

06

What researchers measure

Primary outcomes

  1. Participants Experiencing Dose Limiting Toxicity (DLT)

    DLT was defined as any ixabepilone and/or capecitabine related events requiring study discontinuation during the first two treatment cycles.

    Time frame: From initiation of drug through last day of Cycle 2 (Day 42)

  2. Participants Achieving the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)

    The MTD was defined as the highest dose evaluated for which less than 1/3 of the participants experienced DLT during the first two treatment cycles. If toxicities (e.g. hand-foot syndrome, existing peripheral neuropathy, etc.) occurred or became more severe in later cycles, the recommended Phase II dose was to be determined after due consideration of their severity.

    Time frame: At the end of Cycle 2 (Day 42)

Secondary outcomes

  1. Adverse Events (AEs) and Serious Adverse Events (SAEs)

    AE = any new untoward medical occurrence/worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE = any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Treatment-related=Possible, Probable, or Certain relationship to drug

    Time frame: Baseline to Day 42, continuously

  2. Participant Tumor Response at Study Endpoint

    Tumor response was assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) in which complete response (CR) = disappearance of all target lesions; partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions; progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions; and stable disease (SD) = small changes that do not meet above criteria.

    Time frame: At baseline and after every 42 days (every 2 21-day cycles) after baseline

  3. Mean Ixabepilone Maximum Plasma Concentration (Cmax) in One Dosing Interval

    Cmax = maximum observed plasma concentration of ixabepilone as determined from participant serum samples in one dosing interval.

    Time frame: During Cycle 1 at specified timepoints (Day 1 to Day 8).

  4. Mean Ixabepilone Area Under the Concentration Curve (AUC INF) in One Dosing Interval

    AUC = the average area under the concentration curve (AUC \[INF\]) of ixabepilone as determined from participant serum samples in one dosing interval over 24 hours.

    Time frame: During Cycle 1 at specified timepoints (Day 1 to Day 8).

  5. Mean Ixabepilone Terminal Elimination Half Life (T 1/2) in One Dosing Interval

    T 1/2 = terminal elimination half life as determined from participant serum samples in one dosing interval.

    Time frame: During Cycle 1 at specified timepoints (Day 1 to Day 8).

  6. Mean Ixabepilone Volume of Distribution at Steady State (Vss) in One Dosing Interval

    Vss = volume of distribution at steady state determined from participant serum samples from one dosing interval.

    Time frame: During Cycle 1 at specified timepoints (Day 1 to Day 8).

  7. Mean Ixabepilone Total Body Clearance (CLT) in One Dosing Interval

    CLT = total body clearance as determined from participant serum samples in one dosing interval.

    Time frame: During Cycle 1 at specified timepoints (Day 1 to Day 8).

07

Results

Posted Aug 17, 2011

Participant flow

Participants were recruited from 4 sites in Japan.

Participant flow — Overall Study
MilestoneIxabepilone 32 mg/m^2 + Capecitabine 1650 mg/m^2/DayIxabepilone 40 mg/m^2 + Capecitabine 1650 mg/m^2/DayIxabepilone 40 mg/m^2 + Capecitabine 2000 mg/m^2/Day
Started333
Completed333
Not completed000

Outcome measures

PrimaryParticipants Experiencing Dose Limiting Toxicity (DLT)

DLT was defined as any ixabepilone and/or capecitabine related events requiring study discontinuation during the first two treatment cycles.

Time frame:
From initiation of drug through last day of Cycle 2 (Day 42)
Reported as:
Number · Participants
Participants Experiencing Dose Limiting Toxicity (DLT)
ParticipantsIxabepilone 32 mg/m^2 + Capecitabine 1650 mg/m^2/DayIxabepilone 40 mg/m^2 + Capecitabine 1650 mg/m^2/DayIxabepilone 40 mg/m^2 + Capecitabine 2000 mg/m^2/Day
Participants Experiencing Dose Limiting Toxicity (DLT)000
SecondaryAdverse Events (AEs) and Serious Adverse Events (SAEs)

AE = any new untoward medical occurrence/worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE = any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Treatment-related=Possible, Probable, or Certain relationship to drug

Time frame:
Baseline to Day 42, continuously
Reported as:
Number · Participants
Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsIxabepilone 32 mg/m^2 + Capecitabine 1650 mg/m^2/DayIxabepilone 40 mg/m^2 + Capecitabine 1650 mg/m^2/DayIxabepilone 40 mg/m^2 + Capecitabine 2000 mg/m^2/Day
AEs333
Related AEs333
Discontinued Due to AEs000
SAEs011
Related SAEs011
Discontinued Due to SAEs000
Deaths000
SecondaryParticipant Tumor Response at Study Endpoint

Tumor response was assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) in which complete response (CR) = disappearance of all target lesions; partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions; progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions; and stable disease (SD) = small changes that do not meet above criteria.

Time frame:
At baseline and after every 42 days (every 2 21-day cycles) after baseline
Reported as:
Number · Participants
Participant Tumor Response at Study Endpoint
ParticipantsIxabepilone 32 mg/m^2 + Capecitabine 1650 mg/m^2/DayIxabepilone 40 mg/m^2 + Capecitabine 1650 mg/m^2/DayIxabepilone 40 mg/m^2 + Capecitabine 2000 mg/m^2/Day
CR001
PR112
PD110
SD110
SecondaryMean Ixabepilone Maximum Plasma Concentration (Cmax) in One Dosing Interval

Cmax = maximum observed plasma concentration of ixabepilone as determined from participant serum samples in one dosing interval.

Time frame:
During Cycle 1 at specified timepoints (Day 1 to Day 8).
Reported as:
Geometric mean · ng/mL
Mean Ixabepilone Maximum Plasma Concentration (Cmax) in One Dosing Interval
ng/mLIxabepilone 32 mg/m^2 + Capecitabine 1650 mg/m^2/DayIxabepilone 40 mg/m^2 + Capecitabine 1650 mg/m^2/DayIxabepilone 40 mg/m^2 + Capecitabine 2000 mg/m^2/Day
Mean Ixabepilone Maximum Plasma Concentration (Cmax) in One Dosing Interval164.01 ± 30219.44 ± 13192.13 ± 6
SecondaryMean Ixabepilone Area Under the Concentration Curve (AUC INF) in One Dosing Interval

AUC = the average area under the concentration curve (AUC \[INF\]) of ixabepilone as determined from participant serum samples in one dosing interval over 24 hours.

Time frame:
During Cycle 1 at specified timepoints (Day 1 to Day 8).
Reported as:
Geometric mean · ng·h/mL
Mean Ixabepilone Area Under the Concentration Curve (AUC INF) in One Dosing Interval
ng·h/mLIxabepilone 32 mg/m^2 + Capecitabine 1650 mg/m^2/DayIxabepilone 40 mg/m^2 + Capecitabine 1650 mg/m^2/DayIxabepilone 40 mg/m^2 + Capecitabine 2000 mg/m^2/Day
Mean Ixabepilone Area Under the Concentration Curve (AUC INF) in One Dosing Interval1260.71 ± 11676.46 ± 241417.78 ± 10
SecondaryMean Ixabepilone Terminal Elimination Half Life (T 1/2) in One Dosing Interval

T 1/2 = terminal elimination half life as determined from participant serum samples in one dosing interval.

Time frame:
During Cycle 1 at specified timepoints (Day 1 to Day 8).
Reported as:
Mean · Hours
Mean Ixabepilone Terminal Elimination Half Life (T 1/2) in One Dosing Interval
HoursIxabepilone 32 mg/m^2 + Capecitabine 1650 mg/m^2/DayIxabepilone 40 mg/m^2 + Capecitabine 1650 mg/m^2/DayIxabepilone 40 mg/m^2 + Capecitabine 2000 mg/m^2/Day
Mean Ixabepilone Terminal Elimination Half Life (T 1/2) in One Dosing Interval41.77 ± 944.17 ± 854.27 ± 16
SecondaryMean Ixabepilone Volume of Distribution at Steady State (Vss) in One Dosing Interval

Vss = volume of distribution at steady state determined from participant serum samples from one dosing interval.

Time frame:
During Cycle 1 at specified timepoints (Day 1 to Day 8).
Reported as:
Mean · Liters
Mean Ixabepilone Volume of Distribution at Steady State (Vss) in One Dosing Interval
LitersIxabepilone 32 mg/m^2 + Capecitabine 1650 mg/m^2/DayIxabepilone 40 mg/m^2 + Capecitabine 1650 mg/m^2/DayIxabepilone 40 mg/m^2 + Capecitabine 2000 mg/m^2/Day
Mean Ixabepilone Volume of Distribution at Steady State (Vss) in One Dosing Interval1910.13 ± 4231498.46 ± 1402055.55 ± 795
SecondaryMean Ixabepilone Total Body Clearance (CLT) in One Dosing Interval

CLT = total body clearance as determined from participant serum samples in one dosing interval.

Time frame:
During Cycle 1 at specified timepoints (Day 1 to Day 8).
Reported as:
Mean · L/h
Mean Ixabepilone Total Body Clearance (CLT) in One Dosing Interval
L/hIxabepilone 32 mg/m^2 + Capecitabine 1650 mg/m^2/DayIxabepilone 40 mg/m^2 + Capecitabine 1650 mg/m^2/DayIxabepilone 40 mg/m^2 + Capecitabine 2000 mg/m^2/Day
Mean Ixabepilone Total Body Clearance (CLT) in One Dosing Interval41.52 ± 237.21 ± 742.79 ± 7
PrimaryParticipants Achieving the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)

The MTD was defined as the highest dose evaluated for which less than 1/3 of the participants experienced DLT during the first two treatment cycles. If toxicities (e.g. hand-foot syndrome, existing peripheral neuropathy, etc.) occurred or became more severe in later cycles, the recommended Phase II dose was to be determined after due consideration of their severity.

Time frame:
At the end of Cycle 2 (Day 42)
Reported as:
Number · Participants
Participants Achieving the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
ParticipantsAll Participants With Measurable Disease and Tumor Response
Ixa 40 mg/m^2 + Cap 2000 mg/m^2 MTD3
Ixa 40 mg/m^2 + Cap 2000 ng/m^2 RP2D3

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ixabepilone 32 mg/m^2 + Capecitabine 1650 mg/m^2/Day—0/3 (0%)3/3 (100%)
Ixabepilone 40 mg/m^2 + Capecitabine 1650 mg/m^2/Day—1/3 (33.3%)3/3 (100%)
Ixabepilone 40 mg/m^2 + Capecitabine 2000 mg/m^2/Day—1/3 (33.3%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventIxabepilone 32 mg/m^2 + Capecitabine 1650 mg/m^2/DayIxabepilone 40 mg/m^2 + Capecitabine 1650 mg/m^2/DayIxabepilone 40 mg/m^2 + Capecitabine 2000 mg/m^2/Day
SKIN INFECTIONInfections and infestations0/31/30/3
NEUTROPENIABlood and lymphatic system disorders0/30/31/3
Most frequent other events
Showing 10 of 62
Most frequent other events
EventIxabepilone 32 mg/m^2 + Capecitabine 1650 mg/m^2/DayIxabepilone 40 mg/m^2 + Capecitabine 1650 mg/m^2/DayIxabepilone 40 mg/m^2 + Capecitabine 2000 mg/m^2/Day
HAEMOGLOBIN DECREASEDInvestigations1/32/33/3
PERIPHERAL SENSORY NEUROPATHYNervous system disorders3/33/33/3
NAUSEAGastrointestinal disorders1/33/32/3
DECREASED APPETITEMetabolism and nutrition disorders2/33/33/3
LEUKOPENIABlood and lymphatic system disorders3/33/33/3
NEUTROPENIABlood and lymphatic system disorders3/33/33/3
THROMBOCYTOPENIABlood and lymphatic system disorders0/33/33/3
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROMESkin and subcutaneous tissue disorders2/30/33/3
MYALGIAMusculoskeletal and connective tissue disorders3/33/32/3
ARTHRALGIAMusculoskeletal and connective tissue disorders2/33/33/3

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Ixabepilone 32 mg/m^2 + Capecitabine 1650 mg/m^2/DayIxabepilone 40 mg/m^2 + Capecitabine 1650 mg/m^2/DayIxabepilone 40 mg/m^2 + Capecitabine 2000 mg/m^2/DayTotal
<=18 years0000
Between 18 and 65 years3328
>=65 years0011
Age, Continuous
Age, Continuous(years)Ixabepilone 32 mg/m^2 + Capecitabine 1650 mg/m^2/DayIxabepilone 40 mg/m^2 + Capecitabine 1650 mg/m^2/DayIxabepilone 40 mg/m^2 + Capecitabine 2000 mg/m^2/DayTotal
Mean54.0 ± 13.0052.7 ± 4.7352.7 ± 20.2653.1 ± 12.28
Sex: Female, Male
Sex: Female, Male(Participants)Ixabepilone 32 mg/m^2 + Capecitabine 1650 mg/m^2/DayIxabepilone 40 mg/m^2 + Capecitabine 1650 mg/m^2/DayIxabepilone 40 mg/m^2 + Capecitabine 2000 mg/m^2/DayTotal
Female3339
Male0000
Region of Enrollment
Region of Enrollment(participants)Ixabepilone 32 mg/m^2 + Capecitabine 1650 mg/m^2/DayIxabepilone 40 mg/m^2 + Capecitabine 1650 mg/m^2/DayIxabepilone 40 mg/m^2 + Capecitabine 2000 mg/m^2/DayTotal
Japan3339
08

Study locations

4 sites
  • Local Institution
    Matsuyama-Shi, Ehime 7910280, Japan
  • Local Institution
    Maebashi-Shi, Gunma 371-8511, Japan
  • Local Institution
    Sunto-Gun, Shizuoka 411-8777, Japan
  • Local Institution
    Osaka, 540-0006, Japan
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2011, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2007
First posted
Dec 5, 2007
Start
Feb 2008
Primary completionActual
Jan 2010
CompletionActual
Jan 2010
Results first posted
Aug 17, 2011
Last update
Mar 10, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00568022
Lead sponsor
R-Pharm
Responsible party
Sponsor
First posted
Dec 5, 2007
Start date
Feb 2008
Primary completion
Jan 2010
Completion
Jan 2010
Results posted
Aug 17, 2011
Last update
Mar 10, 2016

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ixabepilone · Capecitabine

Start the discussion